Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Dena Jalbert, CEO of Align Advisory Services, breaks down the M&A outlook for 2026 as AI costs, debt, valuations and economic uncertainty reshape deal-making.
LSEG Consumer Research Director Jharonne Martis breaks down retail earnings, the K-shaped consumer and what inflation and rising costs mean for spending.
Serve Robotics CEO Ali Kashani discusses expanding beyond Uber, adding new delivery partners and scaling autonomous robots as delivery moves into the mainstream
Citrotech CEO Wes Bolsen discusses how innovative building materials could prevent fires, slow their spread and reshape the future of fire-safe construction.
